Skip to content
Off-Label Risks: Compliance Matters Now More Than Ever episode artwork

Jun 3, 2024 24 min

Off-Label Risks: Compliance Matters Now More Than Ever

from DarshanTalks Podcast Hosted by Darshan Kulkarni

Send us Fan Mail We shed light on the complexities surrounding off-label promotion and reimbursement in the pharmaceutical industry. We discuss the following: What does off-label mean from a reimbursement standpoint? Lessons from the US v. Eli Lilly 2009 case How do recent court decisions impact off-label promotion? United States v. Caronia and US v. Facteau How are weight loss drugs, initially approved for treating diabetes, reimbursed within Medicare and Medicaid? How are compounded drugs reimbursed? Could a company be held accountable for off-label use of a drug due to compounded products? Are weight loss drugs exempted from reimbursement? Support the show www.kulkarnilawfirm.com

Episode details come from the podcast's RSS feed.

Embed this episode

Ready to play

Off-Label Risks: Compliance Matters Now More Than Ever

0:00 24:35

No transcript yet.

Requests help us decide what to transcribe next.

Frequently asked questions

How long is this episode of DarshanTalks Podcast?

This episode is 24 minutes long.

When was this DarshanTalks Podcast episode published?

This episode was published on June 3, 2024.

Can I download this DarshanTalks Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.